-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Teladoc Health, Raises Price Target to $9

Benzinga·11/02/2026 21:38:23
UBS analyst Kevin Caliendo maintains Teladoc Health (NYSE:TDOC) with a Neutral and raises the price target from $6.5 to $9.